Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Scinai Immunotherapeutics Ltd ADR (SCNI)

Scinai Immunotherapeutics Ltd ADR (SCNI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities PR Newswire - Mon Apr 6, 6:00AM CDT

JERUSALEM , April 6, 2026 /PRNewswire/ --  Scinai Immunotherapeutics Ltd.  (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company developing inflammation and immunology...

SCNI : 0.5807 (-1.64%)
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration PR Newswire - Wed Apr 1, 6:35AM CDT

JERUSALEM , April 1, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.  (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company operating a dual R&D and CDMO business...

SCNI : 0.5807 (-1.64%)
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026 PR Newswire - Thu Mar 19, 6:50AM CDT

JERUSALEM , March 19, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics,...

SCNI : 0.5807 (-1.64%)
Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price PR Newswire - Mon Mar 16, 3:05PM CDT

JERUSALEM , March 16, 2026 /PRNewswire/ --  Scinai Immunotherapeutics Ltd.  (Nasdaq: SCNI) ("Scinai" or the "Company"), today announced that it received a written notification from...

SCNI : 0.5807 (-1.64%)
Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept PR Newswire - Mon Mar 2, 8:20AM CST

JERUSALEM , March 2, 2026 /PRNewswire/ --  Scinai Immunotherapeutics Ltd.  (Nasdaq: SCNI);("Scinai" or the "Company"), today announced the execution of a Second Amendment to its Binding...

SCNI : 0.5807 (-1.64%)
Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform PR Newswire - Wed Feb 25, 7:11AM CST

JERUSALEM , Feb. 25, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI);("Scinai", or the "Company"), today announced that, following an additional review by the Israel...

SCNI : 0.5807 (-1.64%)
Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm PR Newswire - Tue Feb 17, 6:00AM CST

JERUSALEM , Feb. 17, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd .  (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology...

SCNI : 0.5807 (-1.64%)
Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL PR Newswire - Wed Jan 7, 6:00AM CST

JERUSALEM , Jan. 7, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI); ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology (I&I)...

SCNI : 0.5807 (-1.64%)
Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances PR Newswire - Tue Dec 2, 2025

JERUSALEM , Dec. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing innovative inflammation and immunology...

SCNI : 0.5807 (-1.64%)
Scinai Immunotherapeutics Secures Grant to Boost CDMO Capabilities Tipranks - Tue Oct 7, 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Scinai Immunotherapeutics...

SCNI : 0.5807 (-1.64%)

Barchart Exclusives

Iran Ceasefire, Bank Earnings and Other Key Things to Watch this Week Barchart - Sun Apr 12, 12:00PM CDT
Markets face extraordinary uncertainty following the collapse of lengthy U.S.-Iran diplomatic talks that ended with no deal, as Vice President J.D. Vance confirmed Iranian officials "have chosen not to accept our terms." Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.